- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about REGN
Recent news which mentions REGN
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
September 16, 2022
From Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
From Benzinga
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
September 15, 2022
From Benzinga
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
September 14, 2022
From Benzinga
From Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
September 13, 2022
From Benzinga
From Benzinga
Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity
September 12, 2022
Tickers
REGN
From Benzinga
9 Analysts Have This to Say About Regeneron Pharmaceuticals
September 09, 2022
Tickers
REGN
From Benzinga
Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know
September 09, 2022
Tickers
REGN
From Benzinga
'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added
September 09, 2022
Tickers
REGN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
From Benzinga
What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
September 09, 2022
Tickers
REGN
From Benzinga
Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday
September 09, 2022
From Benzinga
US Stock Futures Surge; Fed Speakers In Focus
September 09, 2022
From Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
September 09, 2022
From Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
From Benzinga
Why Regeneron Pharmaceuticals Stock Is Crushing It Today
September 08, 2022
From Motley Fool
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
September 08, 2022
From Benzinga
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
September 08, 2022
From Benzinga
AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday
September 08, 2022
From Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
September 08, 2022
From Benzinga
Regeneron Pharmaceuticals Whale Trades For September 06
September 06, 2022
Tickers
REGN
From Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
September 06, 2022
From Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,900 Today
September 02, 2022
Tickers
REGN
From Benzinga
From Benzinga
From Benzinga
5 Top Stocks Cathie Wood Is Selling This Week
August 26, 2022
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.